Explore the mechanism of action of FABHALTA^® (iptacopan)

FOR PATIENTS WITH IgAN

The alternative complement pathway is thought to contribute to the pathogenesis of IgAN^1,2

Image showing the multi-hit model of IgAN. In IgAN there is an increase in galactose-deficient IgA1 (Gd-IgA1). This induces production of autoantibodies. Autoantibodies bind to Gd-IgA1 to form immune complexes. Immune complex deposition in the mesangium of the kidneys can activate multiple pathways.

FOR ADULTS WITH PRIMARY IgAN AT RISK OF DISEASE PROGRESSION

FABHALTA is the first and only oral treatment to target the alternative complement pathway¹

Image showing the mechanism of action of Fabhalta® (iptacopan). Fabhalta targets the alternative pathway. Fabhalta binds to Factor B of the alternative complement pathway and regulates the cleavage of C3, generation of downstream effectors, and the amplification of the terminal pathway. By binding to Factor B, Fabhalta inhibits the alternative pathway. Fabhalta is a complement Factor B inhibitor. Not a steroid.

See how FABHALTA works in IgAN¹

coming soon

See how FABHALTA was studied in IgAN

View trial design

Start your patients on FABHALTA

Definitions and References

Definitions
C3, complement 3; C3b, complement 3b; C5, complement 5; Gd-IgA1, galactose-deficient immunoglobulin A1; IgAN, immunoglobulin A nephropathy.

References
1. Fabhalta. Prescribing information. Novartis Pharmaceuticals Corp.
2. Lim RS, Yeo SC, Barratt J, Rizk DV. An update on current therapeutic options in IgA nephropathy. J Clin Med. 2024;13(4):947. doi:10.3390/jcm13040947